Special Issue "Clinical Management of Parkinson's Symptoms"

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Clinical Neurology".

Deadline for manuscript submissions: 10 September 2023 | Viewed by 2421

Special Issue Editors

Research Department, Consorci Sanitari Alt Penedès - Garraf, Avinguda de l’Espirall 61, 08720 Vilafranca del Penedès, Barcelona, Spain
Interests: Parkinson's disease; ICT for healthcare; geriatrics; epidemiology
Neurology Department, Neurodegenerative Diseases Research Group (Vall D'Hebron Research Institute), Vall D'Hebron University Campus, Passeig Vall D'Hebron 119-129, 08035 Barcelona, Spain
Interests: Parkinson's disease; movement disorders; biomarkers; neuroimaging; genetics

Special Issue Information

Dear Colleagues,

Parkinson disease (PD) is the second most frequent neurodegenerative disease after Alzheimer´s disease, with an age-standardized annual incidence rate of 160 per 100,000 subjects aged 65 years or older. People living with PD present a wide variety of symptoms, including motor symptoms (bradykinesia, rigidity, freezing of gait, etc.), and non-motor symptoms (depression, anxiety, disautonomic features, etc.). As the disease progresses, the effect of the medication decreases over time (wearing off), leading to fluctuating and difficult-to-control symptoms and thus greatly worsening patients’ quality of life. That patients often do not perceive the manifestations of the disease, and therefore cannot accurately report their time course, further complicates therapeutic adjustment.

This Special Issue will include research on the early identification of the various symptoms of Parkinson's disease or their fluctuation via different means, such as new questionnaires or wearables. Research on progression markers aiming to enhance the understanding of these symptoms is also welcome. We welcome papers aimed at improving the clinical control of patients by any means, including innovations in the care process and non-pharmacological therapies.

Dr. Alejandro Rodríguez-Molinero
Dr. Jorge Hernández-Vara
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • idiopathic Parkinson's disease
  • symptom assessment
  • dyskinesias
  • hypokinesia
  • rigidity
  • extrapyramidal
  • wearing off
  • freezing of gait
  • non-motor symptoms
  • wearable electronic devices
  • drug therapy
  • electric stimulation therapy
  • early medical intervention
  • non-pharmacological treatments

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Assessing the Feasibility of Using Electrochemical Skin Conductance as a Substitute for the Quantitative Sudomotor Axon Reflex Test in the Composite Autonomic Scoring Scale and Its Correlation with Composite Autonomic Symptom Scale 31 in Parkinson’s Disease
J. Clin. Med. 2023, 12(4), 1517; https://doi.org/10.3390/jcm12041517 - 14 Feb 2023
Viewed by 393
Abstract
The Composite Autonomic Scoring Scale (CASS) is a quantitative scoring system that integrates the sudomotor, the cardiovagal, and the adrenergic subscores, and the Composite Autonomic Symptom Scale 31 (COMPASS 31) is based on a well-established comprehensive questionnaire designed to assess the autonomic symptoms [...] Read more.
The Composite Autonomic Scoring Scale (CASS) is a quantitative scoring system that integrates the sudomotor, the cardiovagal, and the adrenergic subscores, and the Composite Autonomic Symptom Scale 31 (COMPASS 31) is based on a well-established comprehensive questionnaire designed to assess the autonomic symptoms across multiple domains. We tested the hypothesis that electrochemical skin conductance (Sudoscan) can be a substitute for the quantitative sudomotor axon reflex test (QSART) in the sudomotor domain and assessed its correlation with COMPASS 31 in patients with Parkinson’s disease (PD). Fifty-five patients with PD underwent clinical assessment and cardiovascular autonomic function tests and completed the COMPASS 31 questionnaire. We compared the modified CASS (integrating the Sudoscan-based sudomotor, adrenergic, and cardiovagal subscores) and CASS subscores (the sum of the adrenergic and cardiovagal subscores). The total weighted score of COMPASS 31 was significantly correlated with both the modified CASS and the CASS subscore (p = 0.007 and p = 0.019). The correlation of the total weighted score of COMPASS 31 increased from 0.316 (CASS subscores) to 0.361 (modified CASS). When we added the Sudoscan-based sudomotor subscore, the case numbers for autonomic neuropathy (AN) increased from 22 (40%, CASS subscores) to 40 (72.7%, modified CASS). The modified CASS not only better reflects the exact autonomic function, but also improves the characterization and quantification of AN in patients with PD. In areas in which a QSART facility is not easily available, Sudoscan could be a time-saving substitution. Full article
(This article belongs to the Special Issue Clinical Management of Parkinson's Symptoms)
Show Figures

Figure 1

Article
Sex Differences in Motor and Non-Motor Symptoms among Spanish Patients with Parkinson’s Disease
J. Clin. Med. 2023, 12(4), 1329; https://doi.org/10.3390/jcm12041329 - 07 Feb 2023
Viewed by 1795
Abstract
Background and objective: Sex plays a role in Parkinson’s disease (PD) mechanisms. We analyzed sex difference manifestations among Spanish patients with PD. Patients and Methods: PD patients who were recruited from the Spanish cohort COPPADIS from January 2016 to November 2017 were included. [...] Read more.
Background and objective: Sex plays a role in Parkinson’s disease (PD) mechanisms. We analyzed sex difference manifestations among Spanish patients with PD. Patients and Methods: PD patients who were recruited from the Spanish cohort COPPADIS from January 2016 to November 2017 were included. A cross-sectional and a two-year follow-up analysis were conducted. Univariate analyses and general linear model repeated measure were used. Results: At baseline, data from 681 PD patients (mean age 62.54 ± 8.93) fit the criteria for analysis. Of them, 410 (60.2%) were males and 271 (39.8%) females. There were no differences between the groups in mean age (62.36 ± 8.73 vs. 62.8 ± 9.24; p = 0.297) or in the time from symptoms onset (5.66 ± 4.65 vs. 5.21 ± 4.11; p = 0.259). Symptoms such as depression (p < 0.0001), fatigue (p < 0.0001), and pain (p < 0.00001) were more frequent and/or severe in females, whereas other symptoms such as hypomimia (p < 0.0001), speech problems (p < 0.0001), rigidity (p < 0.0001), and hypersexuality (p < 0.0001) were more noted in males. Women received a lower levodopa equivalent daily dose (p = 0.002). Perception of quality of life was generally worse in females (PDQ-39, p = 0.002; EUROHIS-QOL8, p = 0.009). After the two-year follow-up, the NMS burden (Non-Motor Symptoms Scale total score) increased more significantly in males (p = 0.012) but the functional capacity (Schwab and England Activities of Daily Living Scale) was more impaired in females (p = 0.001). Conclusion: The present study demonstrates that there are important sex differences in PD. Long-term prospective comparative studies are needed. Full article
(This article belongs to the Special Issue Clinical Management of Parkinson's Symptoms)
Show Figures

Figure 1

Back to TopTop